+34 620 107 537info@nanbiosis.com

U10. Drug Formulation

Ciber bbn

U10. Drug Formulation

    • Scientific Director: Prof. José Luis Pedraz joseluis.pedraz@ehu.es
    • Scientific Coordinator: Dr. Idoia Gallego Garrido idoiagallego@hotmail.com
    • Entities: Universidad del País Vasco (UPV/EHU)
    • Address: Pharmacy & Pharmac. Technology Lab.; Facultad de Farmacia, C/Paseo de la Universidad 7, 01006 Vitoria-Gasteiz (Spain)
    • Phone: +34 653593042
    • Fax: +34 945 013040
    • Web: NANOBIOCEL UPV/EHU

UPV-EHU

Order request

Description

Located at the Faculty of Pharmacy, University of the Basque Country (UPV/EHU), Campus of Alava in Vitoria. The Unit is led by Prof. José Luis Pedraz and consists of large laboratories for: cell culture, chromatography equipment, sample preparation and characterization and one specific for scale preparation of pharmaceutical formulations. Recently the group has incorporated 3D bioprinters of last generation with different technologies based on extrusion, ink jet, among others. It has also incorporated a self-assembly equipment of nanoparticles based on microfluidic technologies.

This Unit has the capacity to design and evaluate dosage forms both classical and new dosage forms of biotech drugs, DNA, RNA and vaccines using different methodologies based on micro and nano-medicine and the latter technology based on the microencapsulation of cells, peptides, proteins, and in general of biotech products, as well as the development and design of non-viral vectors for gene therapy, is one of the biggest singularities of this Unit. It counts with the most advanced equipment for micro and nano encapsulation.

The aim of the Unit is to determine experimentally all the variables needed to develop an optimal formulation and work instructions for preparing final pharmaceutical products.

The pharmaceutical technology applied to drug development involves the selection of materials and procedures that can be adapted to different processes that lead to specific pharmaceutical forms. To do that, the Unit10 counts with the most advanced equipment to cover the development for all the steps of the process.

One of the singularities of this Units is that is GLP certified by the Spanish Medicament Agency

U10. Services & Rates

Active projects

Title Fundin: Organism Call: Funding source Role
RTC-2016-4770-1 Development of a new bioadhesive for the treatment of Pterigium. Biotape
Ministerio de Economía, Industría y Competitividad (MINECO) Retos Colaboración 2016 Partner
RTC-2016-5451-1 Development of Bioprinting and Bioink systems for cartilage and bone repair
Ministerio de Economía, Industria y Competitividad (MINECO) Retos Colaboración 2016 Partner
GA: 783132 POSITION-II “A pilot line for the next generation of smart catheters and implants”
Electronic Component Systems for European Leadership Joint Undertaking (JU) - ECSEL JU H2020-ECSEL-2017-1-IA-two-stage Partner
GA: 645991 DRIVE – Diabetes-Reversing Implants for Enhanced viability and long-term efficacy Unión Europea (Comisión Europea) H2020-NMP-2014-two-stage Partner
SAF2017-90810-REDI Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA»
-ICTS 2017
Coordinator

Other projects

Ref Title Funding Organism Unit Role
RTC-2016-4770-1 DEVELOPMENT OF A NEW BIOADHESIVE FOR PTERIGIUM SURGERY. BIOTAPE MINISTERIO DE ECONOMIA, INDUSTRIA Y COMPETITIVIDAD. Participant
RTC-2016-5451-1 DEVELOPMENT OF BIOIMPRESSION SYSTEMS AND BIOTINES FOR THREE-DIMENSIONAL CARTILAGE AND BONE REGENERATION MINISTERIO DE ECONOMIA, INDUSTRIA Y COMPETITIVIDAD. Participant
RTC-2015-3303-1 Lipid solid nanoparticles for subcutaneous administration of antitumor marine compounds - UNDERLIPIDS MINISTERIO DE ECONOMIA Y COMPETITIVIDAD

Publications

2016

  • Grijalvo S., Puras G., Zarate J., Pons R., Pedraz J.L., Eritja R. et al. Nioplexes encapsulated in supramolecular hybrid biohydrogels as versatile delivery platforms for nucleic acids. RSC Advances. 2016;6(46):39688-39699.
  • Moreno-Sastre M., Pastor M., Esquisabel A., Sans E., Vinas M., Fleischer A. et al. Pulmonary delivery of tobramycin-loaded nanostructured lipid carriers for Pseudomonas aeruginosa infections associated with cystic fibrosis. International Journal of Pharmaceutics. 2016;498(1-2):263-273.
  • Moreno-Sastre M., Pastor M., Esquisabel A., Sans E., Vinas M., Bachiller D. et al. Stability study of sodium colistimethate-loaded lipid nanoparticles. Journal of Microencapsulation. 2016;33(7):636-645.
  • Garcia-Orue I., Gainza G., Gutierrez F.B., Aguirre J.J., Evora C., Pedraz J.L. et al. Novel nanofibrous dressings containing rhEGF and Aloe vera for wound healing applications. International Journal of Pharmaceutics. 2016;:-.
  • Ojeda E., Puras G., Agirre M., Zarate J., Grijalvo S., Eritja R. et al. The role of helper lipids in the intracellular disposition and transfection efficiency of niosome formulations for gene delivery to retinal pigment epithelial cells. International Journal of Pharmaceutics. 2016;503(1-2):115-126.
  • Ojeda E., Puras G., Agirre M., Zarate J., Grijalvo S., Eritja R. et al. The influence of the polar head-group of synthetic cationic lipids on the transfection efficiency mediated by niosomes in rat retina and brain. Biomaterials. 2016;77:267-279.

News U10

29 Apr

CRISPR technologies for Cystic Fibrosis treatment

Cystic fibrosis is an inherited genetic disease that mainly affects the lungs and the digestive system On April 6, the first meeting was held, on the one hand, with people with Cystic Fibrosis and the Euskadi Cystic Fibrosis Association (Arnasa) and, on the other, with the NanoBioCel research group of the CIBER-BBN and the University [...]

05 Apr

1st Meeting with Cystic Fibrosis Patiens (NanoBioCel -ARNASA)

Cystic Fibrosis is a genetic disorder that affects mostly the lungs, but also the pancreas, liver, kidneys, and intestine. It is a genetic, degenerative and chronic disease, with a population incidence is 1 in 5,000, so it is considered among the so called “Rare Diseases” The most common symptoms are continuous colds, repeated infections, decreased lung capacity, impossibility of fat absorption and [...]

22 Mar

The results of POSITION II highlighted by CORDIS: A pan-European alliance for the next generation of smart catheters

In the picture: microencapsulated cardiospheres 10X Captured Brightfield with DM_RGB_Brightfield with DM The European project POSITION-II has been selected for publication in the ‘Results in Brief’ section of the Community Research and Development Information Service (CORDIS) website. CORDIS is the European Commission’s primary source of results from the projects funded by the EU’s framework programmes [...]

15 Feb

AWARDS of the Academy of Pharmacy of Castilla y León 2021 to researchers from NANBIOSIS U10

The leader of the NanoBioCell Group form CIBER-BBN and UPV/EHU, Jose Luis Pedraz, and the reaearches Laura Saenz del Burgo and Markel Lafuente have received the 2021 Award from the Academy of Pharmacy of Castilla y León, on February 4, at the city ​​of Salamanca, for the work entitled: “Design and Characterization of a biotin [...]

13 Jan

Best Emergeging Researcher Award in the Biomedical Area to Edorta Santos

Edorta Santos Vizcaíno has been awarded as Best Emerging Researcher in the biomedical area by the Bioaraba Health Research Institute in the XXII edition of the Research and Innovation Conference. This award aims to recognize the work of researchers under the age of 40 who carry out their research activity in any public center of [...]

26 Nov

New Equipment available for the Regenerative Medicine Research Line of the U10 of NANBIOSIS

The Unit 10 of Drug Formulation of the ICTS NANBIOSIS coordinated by the CIBER-BBN NanoBioCel group directed by Jose Luis Pedraz, which belongs to the University of the Basque Country, has been present at the signing of the agreement that gives support by the Provincial Council of Alava within the framework of the Advance Pharma [...]

14 Oct

Results of the POSITION-II Project “A pilot line for the next generation of smart catheters and implants”

Cáceres, October 14th, 2021 POSITION II has received funding within the Electronic Components and Systems for European Leadership Joint Undertaking (ECSEL JU) in collaboration with the European Union’s H2020 Framework Programme (H2020/2014-2020) and National Authorities, under grant agreement Ecsel-783132-Position-II-2017-IA. It promotes innovation in smart medical instruments and focuses in the next generation of smart catheters [...]

30 Sep

Scientific Communication course

We want to invite you to a practical and short course of Introduction to Scientific Communication organized by CIBER-BBN and NanoBioCellGroup – NANBIOSIS U10 Drug Formulation Unit. The course will take place on the 5th (two hours from 9:00 am to 11:00 am) 6 and October 7 (4 hours from 9:00 a.m. to 1:00 p.m.) [...]

27 Jul

Characterization of encapsulated porcine cardiosphere-derived cells for cardiac regeneration.

Researchers of NANBIOSIS U10 Drug Formulation unit of CIBER-BBN and UPV/EHU and NANBIOSIS U14 Cell Therapy unit and U24 Medical imaging unit at CCMIJU have participated in a research that proposes the use of encapsulated cardiosphere-derived cells (CDC), obtained from heart tissue, as regenerative cell therapy. “The encapsulation of the cells has been carried out [...]

04 Mar

Reversing pulmonary fibrosis has been achieved in murine models with peptide-loaded nanoparticles

A new study with participation of NANBIOSIS Unit 10 Drug Formulation unit of CIBER-BBN and UPV/EHU, has succeeded in preventing and reversing pulmonary fibrosis in experimental models with PLGA / PEI nanoparticles loaded with the GSE4 peptide. These results are the first step to study its possible antifibrotic effect in patients with idiopathic pulmonary fibrosis [...]